Key result
Persistent AKI at discharge after TAVI is linked to ~2-fold higher long-term mortality.
Why the study?
Does persistent acute kidney injury at hospital discharge increase short-term and long-term mortality in patients undergoing transcatheter aortic valve implantation?
Cohort (n=1,540)
Yes
Does persistent acute kidney injury at hospital discharge increase short-term and long-term mortality in patients undergoing transcatheter aortic valve implantation?
Persistent acute kidney injury at hospital discharge occurs in 6.1% of TAVI patients—predicted by lower baseline eGFR, male sex, and transapical access—and independently doubles both 1-year and long-term mortality.
Answers are grounded in this paper and cite their sources.
Persistent AKI at TAVI discharge identifies high-risk patients for closer follow-up; leaves open whether mitigating AKI improves long-term survival.
Background The occurrence of persistent acute kidney injury (pAKI) following transcatheter aortic valve implantation (TAVI) has serious implications. Methods There were 1540 patients undergoing and surviving TAVI included in the nationwide SWEDEHEART registry between 2008 and 2015. Creatinine was measured at baseline and discharge, and those with baseline estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m 2 or dialysis were excluded. pAKI was defined by and encompassing theValve Academic Research Consortium-2 (VARC-2) criteria: increase in serum creatinine concentration ≥26.5 μmol/L or increase by ≥50% (1.5×), or start of in-hospital dialysis until hospital discharge. Logistic regression analysis was used to find baseline factors associated with pAKI. Adjusted Cox regression analysis was used to assess the association of pAKI with mortality. Median follow-up was 1.8 years (IQR 0.7–3.0). Results pAKI occurred in 6.1% (n=94) of the patients (71.3% male). These patients had higher creatinine level (117±50 vs 100±35 mmol/L, p<0.001), but similar baseline eGFR (59±21 vs 56±23 mL/min/1.73 m 2 , p=0.18) and received higher contrast volume (129 mL ±89 vs 110 mL ±78, p=0.027). On multivariable logistic regression analysis, pAKI was predicted by eGFR (OR 0.88, 95% CI (0.79 to 0.98), p=0.019), male gender (OR 2.68, 95% CI (1.63 to 4.38), p<0.001) and apical access (OR 2.23, 95% CI (1.35 to 3.69), p=0.002), whereas contrast volume/10 mL (OR 1.02, 95% CI (1.00 to 1.05), p=0.052) did not reach statistical significance. Mortality at 1 year/end of follow-up was 10.4%/26.9%. pAKI was associated with a doubled risk of death (HR 2.04, 95% CI (1.49 to 2.81), p<0.001). Conclusion Persistent AKI after TAVI occurs in 6.1% and is associated with a doubled long-term mortality. Special efforts to avoid AKI should be taken, especially among vulnerable patients.
No takes yet. Share an insight, caveat, or question.
Vavilis et al. (2017) conducted a cohort in Severe symptomatic aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) (n=1,540). Persistent acute kidney injury (pAKI) at hospital discharge following TAVI vs. No persistent acute kidney injury at hospital discharge was evaluated on Long-term all-cause mortality (HR 2.04, 95% CI 1.49-2.81, p=<0.001). Persistent acute kidney injury at discharge occurred in 6.1% of TAVI patients and doubled long-term mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: